Collegium Pharmaceutical had its Relative Strength (RS) Rating upgraded from 76 to 81 Tuesday.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily tracks price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an RS Rating of above 80 in the early stages of their moves.
Collegium Pharmaceutical is working on a cup without handle with a 42.29 entry. See if it can break out in volume at least 40% above average.
Earnings grew 4% last quarter, up from 3% in the prior report. Revenue also increased, from 23% to 29%.
The company holds the No. 2 rank among its peers in the Medical-Generic Drugs industry group. ANI Pharmaceuticals is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
